Holen Sie sich die Stockscreener-App
0.8307
0.29%
-0.0022
Schlusskurs vom Vortag:
$0.8329
Offen:
$0.8293
24-Stunden-Volumen:
1.12M
Relative Volume:
0.11
Marktkapitalisierung:
$81.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+6.41%
1M Leistung:
+2.05%
6M Leistung:
-84.48%
1J Leistung:
-74.60%
1-Tages-Spanne:
$0.81
$0.8499
1-Wochen-Bereich:
$0.7001
$0.8596
52-Wochen-Spanne:
$0.64
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Firmenname
Atyr Pharma Inc
Sektor
Branche
Telefon
(858) 731-8389
Adresse
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Vergleichen Sie ATYR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.8305 | 81.11M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.31 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.25 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.54 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
903.07 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.59 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-05 | Eingeleitet | Jefferies | Buy |
| 2023-07-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-09-21 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-10 | Eingeleitet | Laidlaw | Buy |
| 2020-08-17 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Eingeleitet | ROTH Capital | Buy |
| 2020-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-12-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Eingeleitet | Citigroup | Neutral |
| 2015-06-01 | Eingeleitet | Citigroup | Buy |
| 2015-06-01 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Atyr Pharma Inc Aktie (ATYR) Neueste Nachrichten
ATyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - marketscreener.com
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Holzer & Holzer, LLC Reminds Investors of Upcoming December - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Deadline Soon: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - PR Newswire
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Barchart.com
aTyr Pharma, Inc. $ATYR Shares Bought by Geode Capital Management LLC - Defense World
ATYR 5-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Inves - GuruFocus
Shareholders SueWallSt in New Class Action Against aTyr Pharma, Inc.Act Now - Nasdaq
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - GlobeNewswire
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit - PR Newswire
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - MarketScreener
Deadline Alert: aTyr Pharma Inc. (ATYR) Shareholders Who - GlobeNewswire
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) should c - GuruFocus
Portnoy Law Firm Announces Class Action on Behalf of aTyr Pharma, Inc. Investors - GlobeNewswire
The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineATYR - Lelezard
Will aTyr Pharma Inc. (471A) stock profit from fiscal stimulusQuarterly Risk Review & Low Volatility Stock Recommendations - Newser
How aTyr Pharma Inc. (471A) stock valuation compares with sectorMarket Trend Review & Consistent Profit Trading Strategies - Newser
ATYR 1-WEEK DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - PR Newswire
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - MarketScreener
Bragar Eagel & Squire, P.C. Urgently Reminds Stockholders - GlobeNewswire
Lost Money on aTyr Pharma, Inc.(ATYR)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewswire
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securi - GuruFocus
Levi & Korsinsky Notifies aTyr Pharma, Inc. (ATYR) InvestorsLead Plaintiff Deadline on December 8, 2025 - Stockhouse
ATYR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that aTyr Pharma, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATYR DEADLINE: Faruqi & Faruqi Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025ATYR - PR Newswire
Shareholders of aTyr Pharma, Inc. (ATYR): Protect Your Rights Before December 8, 2025Contact Levi & Korsinsky - Stockhouse
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - GlobeNewswire
ATYR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages - GlobeNewswire
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - Prime Publishers, Inc.
2025-11-28 | Securities Fraud Class Action Filed Against aTyr Pharma, Inc. (ATYR)Levi & Korsinsky Reminds Investors of December 8, 2025 | NDAQ:ATYR | Press Release - Stockhouse
ATYR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that aTyr Pharma, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Announces that aTyr Pharma Investors Have Opportunity to Lead Class Action Lawsuit - MarketScreener
ATYR Deadline: ATYR Investors with Losses in Excess of $100K Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit - Your Wyoming Link
The Short List — Top 10 Most Shorted Stocks Right Now - Sahm
aTyr Pharma (ATYR) Securities Class Action Pending Over Key Drug's Efficacy -- Hagens Berman - GuruFocus
ATyr Pharma (ATYR) Securities Class Action Pending Over Key Drug's Efficacy -- Hagens Berman - MarketScreener
aTyr Pharma (ATYR) Securities Class Action Pending Over Key Drug's Efficacy — Hagens Berman - Morningstar
ATYR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that aTyr Pharma, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves ForwardHagens Berman - The Malaysian Reserve
aTyr Pharma, Inc. Sued for Securities Law Violations - GlobeNewswire
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman - Barchart.com
Recover Investment Losses: Class Action Initiated Against aTyr Pharma, Inc. (ATYR) - Stockhouse
aTyr Pharma Faces Class Action after Clinical Trial Failure Raises Investor Concerns - TipRanks
ATYR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that aTyr Pharma, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to - GuruFocus
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - WV News
Traws Pharma Inc (TRAW) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Finanzdaten der Atyr Pharma Inc-Aktie (ATYR)
Es liegen keine Finanzdaten für Atyr Pharma Inc (ATYR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Atyr Pharma Inc-Aktie (ATYR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
| Gross Jane A | Director |
Mar 17 '25 |
Buy |
4.00 |
3,750 |
15,000 |
9,750 |
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
0.72%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):